Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Other Non Operating Income (2023 - 2025)

Contineum Therapeutics has reported Other Non Operating Income over the past 3 years, most recently at -$51000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$51000.0 for Q4 2025, down 8.51% from a year ago — trailing twelve months through Dec 2025 was -$165000.0 (down 0.61% YoY), and the annual figure for FY2025 was -$165000.0, down 1.23%.
  • Other Non Operating Income for Q4 2025 was -$51000.0 at Contineum Therapeutics, down from $183000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for CTNM hit a ceiling of $257000.0 in Q4 2023 and a floor of -$167000.0 in Q2 2025.
  • Median Other Non Operating Income over the past 3 years was -$41500.0 (2023), compared with a mean of -$16833.3.
  • Peak annual rise in Other Non Operating Income hit 638.24% in 2025, while the deepest fall reached 2066.67% in 2025.
  • Contineum Therapeutics' Other Non Operating Income stood at $257000.0 in 2023, then plummeted by 118.29% to -$47000.0 in 2024, then decreased by 8.51% to -$51000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$51000.0 (Q4 2025), $183000.0 (Q3 2025), and -$167000.0 (Q2 2025) per Business Quant data.